PT Intanwijaya Internasional Tbk (IDX:INCI)

Intercept Pharmaceuticals Cash Flow Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	22,846	25,836	17,501	24,415	11,036	30,064
Depreciation & Amortization	5,642	5,536	5,469	6,116	6,668	5,782
Other Operating Activities	-16,369	10,222	14,804	-14,419	-33,297	15,138
Operating Cash Flow	12,119	41,594	37,774	16,112	-15,593	50,984
Operating Cash Flow Growth	-79.73%	10.11%	134.45%	-	-	329.59%
Capital Expenditures	-3,145	-2,990	-618.51	-519.79	-1,676	-4,073
Sale of Property, Plant & Equipment	650.59	65	-	-	-	60
Other Investing Activities	16,047	2,688	2,657	-1,090	1,033	1,327
Investing Cash Flow	13,553	-236.64	2,038	-1,610	-643.85	-2,686
Long-Term Debt Issued	-	-	-	-	-	837.82
Long-Term Debt Repaid	-	-2,433	-2,596	-2,752	-2,874	-1,386
Net Debt Issued (Repaid)	-2,553	-2,433	-2,596	-2,752	-2,874	-548.28
Common Dividends Paid	-7,219	-7,219	-	-	-4,864	-3,894
Financing Cash Flow	-9,772	-9,652	-2,596	-2,752	-7,738	-4,442
Foreign Exchange Rate Adjustments	361.78	1,188	130.89	-43.28	-246.78	-73.31
Miscellaneous Cash Flow Adjustments	-	-	-	-	0	-
Net Cash Flow	16,262	32,894	37,348	11,706	-24,221	43,783
Free Cash Flow	8,974	38,605	37,156	15,592	-17,269	46,912
Free Cash Flow Growth	-84.58%	3.90%	138.30%	-	-	474.21%
Free Cash Flow Margin	2.28%	9.88%	9.83%	3.26%	-3.32%	11.91%
Free Cash Flow Per Share	42.97	185.91	178.93	75.08	-83.16	225.91
Cash Interest Paid	161.74	54.02	307.06	26.44	67.51	49.96
Cash Income Tax Paid	8,388	1,010	10,259	3,665	11,782	5,909
Levered Free Cash Flow	12,359	31,481	34,864	13,574	-19,438	40,495
Unlevered Free Cash Flow	12,359	31,481	34,877	13,591	-19,396	40,527
Change in Net Working Capital	5,756	-13,083	-16,311	8,109	32,300	-15,845

Source: S&P Global Market Intelligence. Standard template. Financial Sources.